PDCD1 and breast carcinoma: Additionally, Christmas et al. showed that the combination of entinostat with ICIs, such as anti-PD-1, significantly empowered T cell-mediated antitumor immunity in HER2+ breast cancer and metastatic pancreatic cancer mouse models [21].